IQVIA
About: Iqvia is the result of the 2016 merger of Quintiles, a leading global contract research organization, and IMS Health, a leading healthcare data and analytics provider. The research and development segment focuses primarily on providing outsourced late-stage clinical trials for pharmaceutical, device, and diagnostic firms. The technology and analytics segment provides aggregated information and technology services to clients in the healthcare industry, including pharmaceutical companies, providers, payers, and policymakers, as well as data and analytics capabilities for clinical trials, including virtual trials. The company also has a small contract sales business.
Employees: 90,000
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
20% more funds holding in top 10
Funds holding in top 10: 10 [Q4 2024] → 12 (+2) [Q1 2025]
1.74% more ownership
Funds ownership: 84.76% [Q4 2024] → 86.5% (+1.74%) [Q1 2025]
4% more first-time investments, than exits
New positions opened: 107 | Existing positions closed: 103
3% less repeat investments, than reductions
Existing positions increased: 362 | Existing positions reduced: 375
2% less funds holding
Funds holding: 990 [Q4 2024] → 973 (-17) [Q1 2025]
11% less capital invested
Capital invested by funds: $30.2B [Q4 2024] → $26.8B (-$3.42B) [Q1 2025]
35% less call options, than puts
Call options by funds: $124M | Put options by funds: $191M
Research analyst outlook
7 Wall Street Analysts provided 1 year price targets over the past 3 months
7 analyst ratings
Mizuho Ann Hynes | 17%upside $225 | Outperform Maintained | 25 Jul 2025 |
UBS Dan Leonard | 17%upside $225 | Buy Maintained | 23 Jul 2025 |
Truist Securities Jailendra Singh | 23%upside $235 | Buy Maintained | 23 Jul 2025 |
Barclays Luke Sergott | 3%downside $185 | Equal-Weight Maintained | 23 Jul 2025 |
Baird Eric Coldwell | 2%upside $196 | Neutral Maintained | 23 Jul 2025 |
Financial journalist opinion
Based on 14 articles about IQV published over the past 30 days
